Skip to main content

Advertisement

SpringerLink
Log in

Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objectives

To compare the ablation results, therapeutic responses and adverse reactions between a low dose (1.1 GBq) or high dose (3.7 GBq) of 131I in low-/intermediate-risk differentiated thyroid cancer (DTC) patients. The factors influencing the ablation result and therapeutic response were also analyzed.

Methods

The researchers used a random number table to randomly assign the enrolled patients to the low-dose group or high-dose group at a 1:1 ratio, and assessment of ablation result, therapeutic response, and adverse reactions evaluated 6 ± 3 months after therapy.

Results

A total of 140 patients were enrolled in the study through October 2014–June 2015. Until February 2016, 132 patients completed the trial. 99 patients were re-examined under thyroid-stimulating hormone (TSH) stimulation 3–9 months after 131I therapy. For the low-dose and high-dose groups, the success rates of ablation were 52.7 % (29/55) and 59.1 % (26/44), respectively. The ablation results did not differ significantly between the two groups (P = 0.548). One hundred and thirty two patients were re-examined 2–9 months after 131I therapy. The low-dose group had an excellent response rate of ~80 % (53/66), an indeterminate response rate of ~20 % (13/66), and no cases with a biochemical incomplete response. The high-dose group had an excellent response rate of ~85 % (56/66), an indeterminate response rate of ~11 % (7/66), and a biochemical incomplete response rate of ~4 % (3/66). No significant differences in the therapeutic response were observed between the two groups (P = 0.087). Patients in stage N1b had a significantly lower success rate of ablation than those in stage N0 (P = 0.000). The success rate of ablation increased significantly with lower thyroglobulin (Tg) levels (P = 0.000). A pre-treatment Tg level was significantly associated with a higher excellent response rate (P = 0.002). Pre-treatment-stimulated Tg of 0.47 and 3.09 μg/L were identified as cut-off values for predicting the ablation result and therapeutic response, respectively. The incidences of adverse reactions were 18 % (12/66) and 39 % (26/66) in the low-dose and high-dose groups, respectively, and this difference between the two groups was significant (P = 0.007).

Conclusions

The result of thyroid remnant ablation and the response to therapy did not differ significantly between the two groups. The low-dose group had a lower incidence of adverse reactions than the high-dose group. N1b and pre-treatment-stimulated Tg were factors influencing the ablation result, whereas pre-treatment-stimulated Tg was a factor influencing the therapeutic response. Pre-treatment-stimulated Tg of 0.47 and 3.09 μg/L were identified as cut-off values for predicting the ablation result and therapeutic response, respectively. The study protocol was approved by the Clinical Trials and Biomedical Ethics Committee of our hospital and registered on the Chinese Clinical Trial Registry under the registration number ChiCTR-IOR-15006139.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Stewart B, Wild CP. World cancer report 2014. World: 2015. http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014. Accessed 25 Mar 2016.

  2. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol. 2010;22(6):395–404.

    Article  CAS  Google Scholar 

  3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Mäenpää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One. 2008;3(4):e1885.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–85.

    Article  CAS  PubMed  Google Scholar 

  6. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663–73.

    Article  CAS  PubMed  Google Scholar 

  7. Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun. 2012;33(3):275–82.

    Article  CAS  PubMed  Google Scholar 

  8. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(4):1433–41.

    Article  CAS  PubMed  Google Scholar 

  9. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150(2):105–12.

    Article  CAS  PubMed  Google Scholar 

  10. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab. 2002;87(7):3242–7.

    Article  CAS  PubMed  Google Scholar 

  11. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87(4):1499–501.

    Article  CAS  PubMed  Google Scholar 

  12. Jeon EJ, Jung ED. Diagnostic whole-body scan may not be necessary for intermediate-risk patients with differentiated thyroid cancer after low-dose (1.1 GBq) radioactive iodide ablation. Endocrinol Metab. 2014;29(1):33–9.

    Article  Google Scholar 

  13. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol. 2012;77(1):132–8.

    Article  CAS  Google Scholar 

  15. Castagna MG, Maino F, Cipri C, Pessoa CH, Dias F, Corbo R, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165(3):441–6.

    Article  CAS  PubMed  Google Scholar 

  16. Evans C, Tennant S, Perros P. Thyroglobulin in differentiated thyroid cancer. Clin Chim Acta. 2015;444:310–7.

    Article  CAS  PubMed  Google Scholar 

  17. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J, et al. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid. 2010;20(6):587–95.

    Article  CAS  PubMed  Google Scholar 

  18. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid. 2002;12(8):707–11.

    Article  CAS  PubMed  Google Scholar 

  19. Verburg FA, de Keizer B, Lips CJ, Zelissen PM, de Klerk JM, et al. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol. 2005;152(1):33–7.

    Article  CAS  PubMed  Google Scholar 

  20. Park HJ, Jeong GC, Kwon SY, Min JJ, Bom HS, Park KS, et al. Stimulated serum thyroglobulin level at the time of first dose of radioactive iodine therapy is the most predictive factor for therapeutic failure in patients with papillary thyroid carcinoma. Nuclear Med Moler Imaging. 2014;48(4):255–61.

    Article  CAS  Google Scholar 

  21. Ha S, Oh SW, Kim YK, Koo DH, Jung YH, Yi KH, et al. Clinical outcome of remnant thyroid ablation with low dose radioiodine in korean patients with low to intermediate-risk thyroid cancer. J Korean Med Sci. 2015;30(7):876–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L, et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12(2):121–34.

    Article  PubMed  Google Scholar 

  23. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941–59.

    Article  CAS  PubMed  Google Scholar 

  24. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab. 2001;86(8):3512–5.

    Article  CAS  PubMed  Google Scholar 

  25. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J. 2002;78(916):92–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, 610041, People’s Republic of China

      Yuan Qu, Rui Huang & Lin Li

    Authors
    1. Yuan Qu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Rui Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Lin Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Lin Li.

    Ethics declarations

    Conflict of interest

    No potential conflicts of interest were disclosed.

    Additional information

    Y. Qu and R. Huang are contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Qu, Y., Huang, R. & Li, L. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial. Ann Nucl Med 31, 71–83 (2017). https://doi.org/10.1007/s12149-016-1133-4

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12149-016-1133-4

    Keywords

    Search

    Navigation